Cellebrite DI (CLBT) Stock Price, News & Analysis

Company Overview

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft. It provides Inseyets, a digital forensics software that collects and reviews digital evidence from various digital sources when conducting legally sanctioned investigations. The company's digital forensics software also offers data extraction, decoding capabilities, workflows, and automation capabilities. In addition, it provides Cellebrite Pathfinder, which reduces the time spent manually reviewing digital evidence by automating data analysis and visualization; Smart Search, an open source intelligence tool that automates the collection and review of publicly available online data; and Guardian, a case and evidence management solution. Further, the company offers digital forensic software for enterprises and service providers, including Inseyets for Enterprise, Endpoint Inspector, and Mobile Now; and professional services, such as training and certification services, and other services. It serves federal and state and local agencies. The company was incorporated in 1999 and is headquartered in Petah Tikva, Israel.

Key Stats

• Today's Range: $18.77 to $20.11
• 50-Day Range: $16.78 to $26.00
• 52-Week Range: $10.25 to $26.30
• Volume: 995,829 shs
• Average Volume: 1.40 million shs
• Market Capitalization: $4.75 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $23.43
• Consensus Rating: Buy

Cellebrite DI Stock Analysis - MarketRank™

Cellebrite DI scored higher than 46% of companies evaluated by MarketBeat, and ranked 230th out of 322 stocks in the business services sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.5 / 5
• Analyst Rating: Buy

Consensus Rating

Cellebrite DI has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Cellebrite DI has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 20.00%

Earnings Growth

Earnings for Cellebrite DI are expected to grow by 20.00% in the coming year, from $0.30 to $0.36 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Cellebrite DI is -14.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Cellebrite DI is -14.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Growth Ratio

Cellebrite DI has a PEG Ratio of 4.27. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Cellebrite DI has a P/B Ratio of 12.17. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.19% of the float of Cellebrite DI has been sold short.

Short Interest Ratio / Days to Cover

Cellebrite DI has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Cellebrite DI has recently increased by 19.63%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Cellebrite DI does not currently pay a dividend.

Dividend Growth

Cellebrite DI does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.19% of the float of Cellebrite DI has been sold short.

Short Interest Ratio / Days to Cover

Cellebrite DI has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Cellebrite DI has recently increased by 19.63%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 0.88

News Sentiment

Cellebrite DI has a news sentiment score of 0.88. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.70 average news sentiment score of Business Services companies.

News Coverage This Week

MarketBeat has tracked 11 news articles for Cellebrite DI this week, compared to 5 articles on an average week.

Search Interest

Only 9 people have searched for CLBT on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.

MarketBeat Follows

Only 8 people have added Cellebrite DI to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Cellebrite DI insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 5.70% of the stock of Cellebrite DI is held by insiders.

Percentage Held by Institutions

45.88% of the stock of Cellebrite DI is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

CLBT Stock Analysis - Frequently Asked Questions

How have CLBT shares performed this year?

Cellebrite DI's stock was trading at $22.03 on January 1st, 2025. Since then, CLBT shares have decreased by 10.0% and is now trading at $19.83.
View the best growth stocks for 2025 here.

How were Cellebrite DI's earnings last quarter?

Cellebrite DI Ltd. (NASDAQ:CLBT) posted its earnings results on Thursday, February, 13th. The company reported $0.07 EPS for the quarter, missing the consensus estimate of $0.10 by $0.03. Cellebrite DI had a negative net margin of 70.54% and a positive trailing twelve-month return on equity of 58.70%.

How do I buy shares of Cellebrite DI?

Shares of CLBT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Cellebrite DI own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Cellebrite DI investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), TotalEnergies (TTE) and Southern First Bancshares (SFST).

Company Calendar

• Last Earnings: 2/13/2025
• Today: 4/02/2025
• Next Earnings (Estimated): 5/22/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Business Services
• Industry: Prepackaged software
• Sub-Industry: Computer Software
• Current Symbol: NASDAQ:CLBT
• CIK: 1854587
• Web: www.cellebrite.com
• Phone: 972-73-394-8000
• Fax: 972-3924-7104
• Employees: 900
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $23.43
• High Stock Price Target: $28.00
• Low Stock Price Target: $17.00
• Potential Upside/Downside: +18.1%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 7 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.39)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 66.10
• P/E Growth: 4.27
• Net Income: $-283,010,000.00
• Net Margins: -70.54%
• Pretax Margin: -68.79%
• Return on Equity: 58.70%
• Return on Assets: 13.85%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.92
• Quick Ratio: 1.89

Sales & Book Value

• Annual Sales: $401.20 million
• Price / Sales: 11.84
• Cash Flow: $0.38 per share
• Price / Cash Flow: 52.22
• Book Value: $1.63 per share
• Price / Book: 12.17

Miscellaneous

• Outstanding Shares: 239,470,000
• Free Float: 194,194,000
• Market Cap: $4.75 billion
• Optionable: Optionable
• Beta: 1.52